60 Degrees Pharmaceuticals (SXTP) Cash & Equivalents (2022 - 2026)

60 Degrees Pharmaceuticals (SXTP) has reported Cash & Equivalents for 5 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 3.3% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (down 3.3% YoY), while the FY2025 annual figure was $1.5 million, down 55.43% from the prior year.
• Cash & Equivalents grew to $3.3 million in Q1 2026 per SXTP's latest filing, from $1.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $4.1 million in Q3 2025 and bottomed at $19070.0 in Q2 2023.
• Historically, Cash & Equivalents has averaged $2.0 million across 5 years, with a median of $2.1 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 97.46% — and 2024, when it jumped 9551.25%.
• 60 Degrees Pharmaceuticals' Cash & Equivalents stood at $264865.0 in 2022, then jumped by 708.9% to $2.1 million in 2023, then soared by 58.13% to $3.4 million in 2024, then slumped by 55.43% to $1.5 million in 2025, then jumped by 121.03% to $3.3 million in 2026.
• Business Quant data shows SXTP's Cash & Equivalents at $3.3 million in Q1 2026, $1.5 million in Q4 2025, and $4.1 million in Q3 2025.